These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
231 related articles for article (PubMed ID: 9862681)
41. B7.2-/- mature dendritic cells generate T-helper 2 and regulatory T donor cells in fetal mice after in utero allogeneic bone marrow transplantation. Bhattacharyya S; Cowan MJ Biol Blood Marrow Transplant; 2005 Sep; 11(9):657-71. PubMed ID: 16125636 [TBL] [Abstract][Full Text] [Related]
42. Vascular attack by 5,6-dimethylxanthenone-4-acetic acid combined with B7.1 (CD80)-mediated immunotherapy overcomes immune resistance and leads to the eradication of large tumors and multiple tumor foci. Kanwar JR; Kanwar RK; Pandey S; Ching LM; Krissansen GW Cancer Res; 2001 Mar; 61(5):1948-56. PubMed ID: 11280751 [TBL] [Abstract][Full Text] [Related]
43. Direct effects on antigen-presenting cells and T lymphocytes explain the adjuvanticity of a nontoxic cholera toxin mutant. Yamamoto M; Kiyono H; Yamamoto S; Batanero E; Kweon MN; Otake S; Azuma M; Takeda Y; McGhee JR J Immunol; 1999 Jun; 162(12):7015-21. PubMed ID: 10358143 [TBL] [Abstract][Full Text] [Related]
44. Induction of antitumor immunity by recombinant vaccinia viruses expressing B7-1 or B7-2 costimulatory molecules. Hodge JW; Abrams S; Schlom J; Kantor JA Cancer Res; 1994 Nov; 54(21):5552-5. PubMed ID: 7522961 [TBL] [Abstract][Full Text] [Related]
45. Antigen presentation by B7-nonprofessional APC does not prevent responses to solid tumor cells. Salvadori S; Moran T; Zier K Cell Immunol; 1998 Jan; 183(1):52-9. PubMed ID: 9578719 [TBL] [Abstract][Full Text] [Related]
46. Gene transfer of AIMP1 and B7.1 into epitope-loaded, fibroblasts induces tumor-specific CTL immunity, and prolongs the survival period of tumor-bearing mice. Kim TS; Lee BC; Kim E; Cho D; Cohen EP Vaccine; 2008 Nov; 26(47):5928-34. PubMed ID: 18793691 [TBL] [Abstract][Full Text] [Related]
47. The involvement of transforming growth factor beta in the impaired antitumor T-cell response at the gut-associated lymphoid tissue (GALT). Harada M; Matsunaga K; Oguchi Y; Iijima H; Ito O; Tamada K; Kimura G; Nomoto K Cancer Res; 1995 Dec; 55(24):6146-51. PubMed ID: 8521406 [TBL] [Abstract][Full Text] [Related]
48. B7-1 is superior to B7-2 costimulation in the induction and maintenance of T cell-mediated antileukemia immunity. Further evidence that B7-1 and B7-2 are functionally distinct. Matulonis U; Dosiou C; Freeman G; Lamont C; Mauch P; Nadler LM; Griffin JD J Immunol; 1996 Feb; 156(3):1126-31. PubMed ID: 8557988 [TBL] [Abstract][Full Text] [Related]
49. In vitro priming of tumor-reactive cytolytic T lymphocytes by combining IL-10 with B7-CD28 costimulation. Yang G; Hellström KE; Mizuno MT; Chen L J Immunol; 1995 Oct; 155(8):3897-903. PubMed ID: 7561096 [TBL] [Abstract][Full Text] [Related]
50. Induction of P815 tumor immunity by recombinant Semliki Forest virus expressing the P1A gene. Colmenero P; Liljeström P; Jondal M Gene Ther; 1999 Oct; 6(10):1728-33. PubMed ID: 10516722 [TBL] [Abstract][Full Text] [Related]
51. B7-1 expression by a non-antigen presenting cell-derived tumor. Antonia SJ; Muñoz-Antonia T; Soldevila G; Miller J; Flavell RA Cancer Res; 1995 Jun; 55(11):2253-6. PubMed ID: 7538898 [TBL] [Abstract][Full Text] [Related]
52. Transfection of B7-1 cDNA empowers antigen presentation of blood malignant cells for activation of anti-tumor T cells. Ke X; Jia L; Wang J; Wang D Chin Med J (Engl); 2003 Jan; 116(1):78-84. PubMed ID: 12667394 [TBL] [Abstract][Full Text] [Related]
53. B7.2-Ig fusion proteins enhance IL-4-dependent differentiation of tumor-sensitized CD8+ cytotoxic T lymphocyte precursors. Hiraoka S; Takeuchi N; Bian Y; Nakahara H; Kogo M; Dunussi-Joannopoulos K; Wolf S; Ono S; Fujiwara H Int Immunol; 2005 Aug; 17(8):1071-9. PubMed ID: 16027141 [TBL] [Abstract][Full Text] [Related]
54. Insight into the mechanism(s) through which TNF promotes the generation of T cell-mediated antitumor cytotoxicity by tumor bearer splenic cells. Gorelik L; Bar-Dagan Y; Mokyr MB J Immunol; 1996 Jun; 156(11):4298-308. PubMed ID: 8666801 [TBL] [Abstract][Full Text] [Related]
55. Multiple lineages of tumors express a common tumor antigen, P1A, but they are not cross-protected. Ramarathinam L; Sarma S; Maric M; Zhao M; Yang G; Chen L; Liu Y J Immunol; 1995 Dec; 155(11):5323-9. PubMed ID: 7594546 [TBL] [Abstract][Full Text] [Related]
56. Specific immune induction following DNA-based immunization through in vivo transfection and activation of macrophages/antigen-presenting cells. Chattergoon MA; Robinson TM; Boyer JD; Weiner DB J Immunol; 1998 Jun; 160(12):5707-18. PubMed ID: 9637479 [TBL] [Abstract][Full Text] [Related]
57. Individual differences in the orientation of the cytolytic T cell response against mouse tumor P815. Brichard VG; Warnier G; Van Pel A; Morlighem G; Lucas S; Boon T Eur J Immunol; 1995 Mar; 25(3):664-71. PubMed ID: 7705394 [TBL] [Abstract][Full Text] [Related]
58. Maturation of cytotoxic T lymphocytes against a B7-transfected nonmetastatic tumor: a critical role for costimulation by B7 on both tumor and host antigen-presenting cells. Maric M; Zheng P; Sarma S; Guo Y; Liu Y Cancer Res; 1998 Aug; 58(15):3376-84. PubMed ID: 9699669 [TBL] [Abstract][Full Text] [Related]
59. Generation of primary tumor-specific CTL in vitro to immunogenic and poorly immunogenic mouse tumors. Liu B; Podack ER; Allison JP; Malek TR J Immunol; 1996 Feb; 156(3):1117-25. PubMed ID: 8557987 [TBL] [Abstract][Full Text] [Related]
60. Rejection of a nonimmunogenic melanoma by vaccination with natural melanoma peptides on engineered antigen-presenting cells. Bellone M; Iezzi G; Martin-Fontecha A; Rivolta L; Manfredi AA; Protti MP; Freschi M; Dellabona P; Casorati G; Rugarli C J Immunol; 1997 Jan; 158(2):783-9. PubMed ID: 8992995 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]